Related Experiment Videos
[Allergic thrombocytopenia to heparin]
1Unité de Thrombose-hémostase, CHU Liège.
Revue Medicale De Liege
|August 29, 2001
Summary
Heparin can cause allergic reactions, leading to a dangerous drop in platelet count and blood clots, known as heparin-induced thrombocytopenia type 2 (HIT-2). Promptly stopping heparin and using alternative anticoagulants is crucial for patient safety.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Context:
- Heparin therapy can trigger immune-mediated adverse reactions.
- Heparin-induced thrombocytopenia type 2 (HIT-2) is a serious complication.
- Distinguishing HIT-2 from non-immunologic thrombocytopenia (HIT-1) is critical.
Purpose:
- To describe the mechanism and clinical presentation of HIT-2.
- To differentiate HIT-2 from HIT-1.
- To outline management strategies for HIT-2.
Summary:
- HIT-2 involves immune complexes of heparin and platelet factor 4 (PF4) antibodies.
- Characterized by a >50% platelet count fall between days 5-14 of heparin therapy.
- Causes endothelial damage and increases thrombosis risk.
Impact:
- Immediate heparin cessation is mandatory.
- Requires alternative anticoagulation, such as recombinant hirudin or vitamin K antagonists.
- Thrombosis risk persists post-heparin cessation, necessitating continued monitoring and management.